A startup that sells genetic tests to assess health risks is pulling in millions from high-profile investors, reports CNBC.
Burlingame, Calif.-based Color Genomics most recently raised $80 million, its intended funding total. This funding brings the company's total financing to $150 million, making it one of the most well-funded health technology companies in Silicon Valley, according to CNBC.
The funding comes from investors like General Catalyst, CRV's George Zachary and Laurene Powell Jobs, founder and president of Emerson Collective.
Color Genomics' tests evaluate users for risk of cancer and heart disease, similar to other genomics companies. However, it plans to distinguish itself by exploring preventive tests for neurological health, behavioral health, and family and reproductive medicine.
More articles on data analytics & precision medicine:
NIH certifies Vibrent Health's precision medicine platform
Cancer Treatment Centers of America expands efforts with Foundation Medicine in precision medicine project
Researchers examine how precision medicine may prevent suicide